2025
Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome?
Mestre-Bach G, Potenza M, Granero R, Håkansson A, Gómez-Peña M, Perales I, Vicó À, Uríszar J, Fernández-Aranda F, Sánchez I, Jiménez-Murcia S. Gambling disorder and problematic pornography use: Does co-occurrence influence treatment outcome? Journal Of Behavioral Addictions 2025, 14: 465-479. PMID: 40116860, DOI: 10.1556/2006.2025.00023.Peer-Reviewed Original ResearchConceptsCognitive-behavioral therapyGambling disorderPornography useEmotion regulationGD severityTreatment outcomesCognitive-behavioral therapy approachCognitive-behavioral therapy sessionsTreatment outcomes of individualsCo-occurrence of GDCo-occurrenceMental health concernsImprove treatment adherenceBehavioral addictionsTreatment dropoutOutcomes of individualsWeekly sessionsTreatment adherencePsychopathologyGamblingSessionsDisordersAssociated with higher likelihoodRelapseImpulseKleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women
Munguía L, Baenas-Soto I, Granero R, Fábregas-Balcells M, Gaspar-Pérez A, Rosinska M, Potenza M, Cuquerella Á, Tapia-Martínez J, Cabús-Grange R, Taranilla-Castro A, Macharé-Alberni M, Talón-Navarro M, Fernández-Aranda F, Jiménez-Murcia S. Kleptomania on the impulsive–compulsive spectrum. Clinical and therapeutic considerations for women. Scientific Reports 2025, 15: 7886. PMID: 40050325, PMCID: PMC11885670, DOI: 10.1038/s41598-025-85705-9.Peer-Reviewed Original ResearchConceptsImpulsive-compulsive spectrumDSM-5 criteriaClinical groupsDSM-5Personality featuresSemi-structured clinical interviewTreatment outcomesHarm avoidance scoresCognitive behavioral treatmentHealthy control individualsSample of female patientsImpact treatment outcomesPoor treatment outcomesCompulsive featuresBehavioral treatmentHigher impulsivityAvoidance scoresClinical interviewKleptomaniaInvestigate treatment outcomesCharacteristics of peopleFemale participantsPsychopathologyClinical samplesTreatment approachesEosinophilic esophagitis manifesting as intractable hiccups in an elderly patient: a case report
Jalloul S, Salem J, Karam K, Chamoun C, Chaptini L. Eosinophilic esophagitis manifesting as intractable hiccups in an elderly patient: a case report. Journal Of Medical Case Reports 2025, 19: 99. PMID: 40045389, PMCID: PMC11884032, DOI: 10.1186/s13256-025-05044-1.Peer-Reviewed Original ResearchConceptsDiagnosis of eosinophilic esophagitisEosinophilic esophagitisEosinophil infiltrationSymptoms related to esophageal dysfunctionComputed tomography of the chestSymptoms of eosinophilic esophagitisElevated peripheral eosinophil countPeripheral eosinophil countEsophagitis treatmentRefractory hiccupsBackgroundEosinophilic esophagitisConclusionThis caseEsophageal dysfunctionCase reportWeUpper endoscopyFood impactionIntermittent dysphagiaCase reportEndoscopic findingsDistal esophagusElderly patientsEosinophil countEsophageal mucosaComputed tomographyIntractable hiccupsDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Callari M, Dugo M, Barreca M, Győrffy B, Galbardi B, Vigano L, Locatelli A, Dall’Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies. Nature Communications 2025, 16: 2195. PMID: 40038334, PMCID: PMC11880565, DOI: 10.1038/s41467-025-57293-9.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesBreast cancerEndocrine therapyImmune infiltrationPrediction of pCRAnti-HER2 therapyLuminal A phenotypeHigher immune infiltrationFemale breast cancerHER2 blockadeDeterminants of responseTumor responseInfiltrating lymphocytesCDK4/6 inhibitionAnti-HER2HER2 targetingClinical endpointsER signalingKi67Response groupCancerTherapyTherapeutic targetMolecular changesTumorSafety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Nassar A, Alaiwi S, Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman R, Johnson D, Grynberg S, Shapira R, Kwan J, Woodford R, Long G, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang E, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Herrera M, Foderaro S, Nana F, Kim C, Sackstein P, Parikh K, Desai A, Smith C, Cortellini A, Pinato D, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Gallegos J, Trent J, Nusrat S, Malvar C, McKay R, Neilan T, Choueiri T, Naqash A. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study. Journal For ImmunoTherapy Of Cancer 2025, 13: e009364. PMID: 40032601, PMCID: PMC11877189, DOI: 10.1136/jitc-2024-009364.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHeart NeoplasmsHumansImmune Checkpoint InhibitorsMaleMiddle AgedRetrospective StudiesTreatment OutcomeConceptsImmune checkpoint inhibitor initiationImmune checkpoint inhibitorsTreatment-related adverse eventsObjective response rateProgression-free survivalCardiac metastasisOverall survivalRetrospective studyAnti-cytotoxic T-lymphocyte antigen 4Dose of immune checkpoint inhibitorsEfficacy of immune checkpoint therapyAnti-programmed death-1International multicenter retrospective studyMulticenter international retrospective studyT-lymphocyte antigen-4Non-small cell lung cancerMedian follow-up timeClinical outcomes of patientsICI-based regimensMultiple cardiac metastasesSolid Tumors V.1.1Immune checkpoint therapyResponse Evaluation CriteriaInternational retrospective studyMulticenter retrospective studyEstimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severityMentalisation-based treatment for antisocial personality disorder in males convicted of an offence on community probation in England and Wales (Mentalization for Offending Adult Males, MOAM): a multicentre, assessor-blinded, randomised controlled trial
Fonagy P, Simes E, Yirmiya K, Wason J, Barrett B, Frater A, Cameron A, Butler S, Hoare Z, McMurran M, Moran P, Crawford M, Pilling S, Allison E, Yakeley J, Bateman A. Mentalisation-based treatment for antisocial personality disorder in males convicted of an offence on community probation in England and Wales (Mentalization for Offending Adult Males, MOAM): a multicentre, assessor-blinded, randomised controlled trial. The Lancet Psychiatry 2025, 12: 208-219. PMID: 39978982, DOI: 10.1016/s2215-0366(24)00445-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultAggressionAntisocial Personality DisorderCost-Benefit AnalysisCriminalsEnglandHumansMaleMiddle AgedTreatment OutcomeWalesYoung AdultConceptsOvert Aggression Scale-ModifiedAntisocial personality disorderMentalisation-based treatmentPersonality disorderDSM-5 criteriaReducing aggressive behaviorService supervisionGroup therapy sessionsEffects of thoughtsCriminal justice systemForensic populationsTreatment gainsDSM-5Psychological treatmentPathway servicesTherapy sessionsAggressive behaviorIndividual sessionsJustice systemCommunity probationFollow-up timepointsUsual groupProbationFindings’ generalisability,Trial proceduresNeoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial
Bilen M, Vo B, Liu Y, Greenwald R, Davarpanah A, McGuire D, Shiradkar R, Li L, Midya A, Nazha B, Brown J, Williams S, Session W, Russler G, Caulfield S, Joshi S, Narayan V, Filson C, Ogan K, Kucuk O, Carthon B, Del Balzo L, Cohen A, Boyanton A, Prokhnevska N, Cardenas M, Sobierajska E, Jansen C, Patil D, Nicaise E, Osunkoya A, Kissick H, Master V. Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial. Nature Cancer 2025, 6: 432-444. PMID: 40016487, DOI: 10.1038/s43018-025-00922-5.Peer-Reviewed Original ResearchConceptsNonmetastatic clear cell renal cell carcinomaRenal cell carcinomaClear cell renal cell carcinomaCell renal cell carcinomaCD8+ T cellsT cellsCell carcinomaAdverse eventsStem-like CD8+ T cellsMetastatic renal cell carcinomaPalmar-plantar erythrodysesthesia syndromeSingle-arm clinical trialOral multikinase inhibitorDisease-free survivalPhase 2 trialSecondary end pointsCabozantinib treatmentNeoadjuvant settingStable diseaseBiopsy-provenPartial responseSurgical resectionOverall survivalMultikinase inhibitorMyeloid populationsPatient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis
Sanacora G, Barnett B, Hu B, Goes F, Mathew S, Murrough J, Reti I, Wilkinson S, Anand A. Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D trial secondary analysis. Psychiatry Research 2025, 347: 116411. PMID: 40049091, DOI: 10.1016/j.psychres.2025.116411.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyResistant depressionTreatment adherenceResponse to ketamineECT-treated patientsTreatment outcome measuresInfluence treatment adherencePatient-Centered Outcomes Research InstituteAssociated with greater likelihoodKetamine treatmentIV ketamineAdverse eventsEffect of patients' preferencesPreference effectsPatient preferencesRandomized patients to treatmentKetamineRate of adverse eventsTreatment responseGreater likelihoodPatients to treatmentPhase completionTreatment preferencesDepressionNeuropsychiatric and laboratory outcomes of hepatitis C treatment in an early-treated HIV cohort in Thailand
Ocampo F, Sacdalan C, Pinyakorn S, Paudel M, Wansom T, Poltubtim N, Sriplienchan S, Phanuphak N, Paul R, Hsu D, Colby D, Trautmann L, Spudich S, Chan P. Neuropsychiatric and laboratory outcomes of hepatitis C treatment in an early-treated HIV cohort in Thailand. AIDS Research And Therapy 2025, 22: 20. PMID: 39972347, PMCID: PMC11841302, DOI: 10.1186/s12981-025-00707-x.Peer-Reviewed Original ResearchConceptsWeeks of antiretroviral therapyAcute HIV infectionT-cell countsT cell ratioAntiretroviral therapyPatient Health Questionnaire-9HCV seroconversionDAA treatmentCD4 + and CD8 + T cell countsCD4+ /CD8+ T-cell ratioCD8+ T cell countsDirect-acting antiviral (DAA) therapyAlanine transaminaseCD4+ /CD8+ ratioAspartate transferaseIntravenous drug useEarly HCV infectionSexually transmitted infectionsFollow-up visitPatient Health Questionnaire-9 scoresBackgroundHepatitis C virusHepatitis C treatmentHIV RNAVirological responseDAA therapyPathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening
Sato Y, Torii S, Kawai K, Yahagi K, Kutyna M, Kawakami R, Konishi T, Vozenilek A, Jinnouchi H, Sakamoto A, Mori H, Cornelissen A, Mori M, Tanaka T, Sekimoto T, Kutys R, Ghosh S, Forrest J, Reardon M, Romero M, Kolodgie F, Virmani R, Finn A. Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening. Circulation Cardiovascular Interventions 2025, 18: e014523. PMID: 39965045, PMCID: PMC11827688, DOI: 10.1161/circinterventions.124.014523.Peer-Reviewed Original ResearchConceptsHypoattenuated leaflet thickeningLeaflet thickeningHistological findingsClinical trialsEvaluate histological findingsAortic valve proceduresSelf-expanding transcatheter aortic valvesAortic bioprosthetic valvesAortic valve leafletsInfective endocarditisValve proceduresTranscatheter aortic valveValve thrombosisAortic bioprosthesesSurgical explantationInflammation scoreAortic valveAcute thrombusImplant durationOrganized thrombusBioprosthetic valvesDay groupLeaflet thrombosisThrombusValve leafletsLong-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.
Fava M, Pani L, De Martin S, Cutler A, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, Guidetti C, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study. The Journal Of Clinical Psychiatry 2025, 86 PMID: 39999772, DOI: 10.4088/jcp.24m15438.Peer-Reviewed Original ResearchConceptsDepressive disorderColumbia-Suicide Severity Rating ScaleOpen-label studyDSM-5</i> criteriaFull analysis setMajor depressive disorderMeasures of depressionSeverity Rating ScaleSexual adverse eventsAntidepressant efficacyTreatment-emergent adverse eventsPostbaseline efficacy assessmentAdverse eventsSuicide attemptsUncompetitive antagonistCognitive functionSafety populationEfficacy assessmentRating ScaleEfficacy measuresMDDDouble-blind studyEmergent adverse eventsLong-term treatmentTreatment-related treatment-emergent adverse eventsRisk factors for cut-throughs in intertrochanteric hip fracture fixation Tip-Apex Distance (TAD) <10 mm and Apex-to-Center <4 mm
Levine A, Klug T, Cross J, Salameh M, Riedel M, Leslie M. Risk factors for cut-throughs in intertrochanteric hip fracture fixation Tip-Apex Distance (TAD) <10 mm and Apex-to-Center <4 mm. Injury 2025, 56: 112205. PMID: 39954635, DOI: 10.1016/j.injury.2025.112205.Peer-Reviewed Original ResearchConceptsTip-apex distanceIntertrochanteric hip fracturesHip fractureRisk factorsAnterior-posteriorLevel 1 academic trauma centerSliding hip screwFracture reduction qualityNeck-shaft angleCut-out complicationsTrauma centerHip screwNeck-shaftIntramedullary nailingRetrospective reviewReduction qualityReduced riskIncreased riskFracture typeClinical outcomesRiskComplicationsCohortLateral viewFixation devicesSelinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
Mascarenhas J, Maher K, Rampal R, Bose P, Podoltsev N, Hong J, Chai Y, Kye S, Method M, Harrison C, . Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. Future Oncology 2025, 21: 807-813. PMID: 39911057, PMCID: PMC11916360, DOI: 10.1080/14796694.2025.2461393.Peer-Reviewed Original ResearchConceptsJAK inhibitorsNo dose limiting toxicitiesDose-limiting toxicityAbsolute mean changeSpleen volume reductionPlacebo-controlled studyBaseline to weekTreatment of patientsDose expansionDose escalationLimiting toxicitiesDouble-blindPrimary endpointPhase 3 study designXPO1 inhibitorsMean changeRuxolitinibPatientsSelinexorVolume reductionDosePhase 3InhibitorsJAKMyelofibrosisOptimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage
Li Q, Lv X, Morotti A, Qureshi A, Dowlatshahi D, Falcone G, Sheth K, Shoamanesh A, Murthy S, Viswanathan A, Goldstein J. Optimal Magnitude of Blood Pressure Reduction and Hematoma Growth and Functional Outcomes in Intracerebral Hemorrhage. Neurology 2025, 104: e213412. PMID: 39913881, PMCID: PMC11803522, DOI: 10.1212/wnl.0000000000213412.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCerebral HemorrhageFemaleHematomaHumansHypertensionMaleMiddle AgedTreatment OutcomeConceptsSystolic blood pressure reductionSystolic blood pressureMagnitude of blood pressure reductionATACH-2 trialHematoma expansionMagnitude of SBP reductionAcute kidney injuryATACH-2Blood pressure reductionIntracerebral hemorrhageMm HgSBP reductionPost hoc analysisFunctional outcomesHematoma growthAntihypertensive Treatment of Acute Cerebral Hemorrhage 2Poor outcomeHoc analysisMedian hematoma volumeModified Rankin Scale scoreSevere intracerebral hemorrhagePressure reductionMultivariable logistic regression assessed associationsRisk of poor outcomesAdmission systolic blood pressureSex Differences in Response to a 12-Week Resistance Training Exercise Intervention After Cardiac Surgery: A Proof-of-Concept Intervention Trial
Safdar B, Jarman A, Madsen T, DeLamielleure L, Zhou B, Axtell R, Geirsson A, Mangi A. Sex Differences in Response to a 12-Week Resistance Training Exercise Intervention After Cardiac Surgery: A Proof-of-Concept Intervention Trial. Clinical Therapeutics 2025, 47: 299-306. PMID: 39904658, DOI: 10.1016/j.clinthera.2025.01.002.Peer-Reviewed Original ResearchConceptsResistance training programExercise interventionResistance training exercise interventionResistance-based exercise programsTraining programFunctional capacityMeasurement of hand grip strengthTraditional cardiac rehabilitationResistance-based exerciseHand grip strengthTrends of improvementAcute cardiac eventsExercise programCardiac rehabilitationAerobic exerciseCardiac surgeryIntervention armCardiopulmonary rehabilitationFeasibility trialGrip strengthExercise parametersIntervention trialsControl armSecondary outcomesMeasured pre-Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial
Chew D, Mark D, Li Y, Nanna M, Kelsey M, Daniels M, Davidson-Ray L, Baloch K, Rogers C, Patel M, Anstrom K, Curzen N, Vemulapalli S, Douglas P, Investigators O. Economic Outcomes With Precision Diagnostic Testing Versus Usual Testing in Stable Chest Pain: Results From the PRECISE Randomized Trial. Circulation Cardiovascular Quality And Outcomes 2025, 18: e011008. PMID: 39895495, PMCID: PMC11837965, DOI: 10.1161/circoutcomes.123.011008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, StableComputed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseCost SavingsCost-Benefit AnalysisFemaleFractional Flow Reserve, MyocardialHospital CostsHumansMaleMiddle AgedPredictive Value of TestsProspective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChest painObstructive coronary artery diseaseCoronary computed tomographic angiographyStable chest painCoronary artery bypass surgeryLow-risk patientsSecondary end pointsPrimary composite of deathPrecision strategyComputed tomographic angiographyHealth care system perspectiveComposite of deathUS health care system perspectiveArtery bypass surgeryMedical costsMean cost differenceNonfatal myocardial infarctionCoronary artery diseaseIntention-to-treatPercutaneous coronary interventionUsual testsEstimated total medical costTotal medical costsClinical practice guidelinesRisk patientsInsights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab
Foss F, Kim Y, Scarisbrick J, Akilov O, Ristuccia R, Dwyer K, Wu W, Bagot M. Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab. Journal Of Dermatological Treatment 2025, 36: 2438794. PMID: 39894454, DOI: 10.1080/09546634.2024.2438794.Peer-Reviewed Original ResearchConceptsMogamulizumab-associated rashConcomitant steroid useSezary syndromeAdvanced diseaseMycosis fungoidesSteroid useResponse to mogamulizumabProportion of patientsPercentage of patientsTreatment of patientsConcomitant steroidsRelapsed/refractory patientsLong-term responseMogamulizumabNext treatmentPatient characteristicsPatientsLymphopeniaVorinostatPatient responseFungoidesPFSMycosisSyndromeTreatmentSurgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsDisease ManagementFemaleHepatectomyHumansLiver NeoplasmsTreatment OutcomeConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgeryPain Coping Skills Training for Patients Receiving Hemodialysis
Dember L, Hsu J, Mehrotra R, Cavanaugh K, Kalim S, Charytan D, Fischer M, Jhamb M, Johansen K, Becker W, Pellegrino B, Eneanya N, Schrauben S, Pun P, Unruh M, Morasco B, Mehta M, Miyawaki N, Penfield J, Bernardo L, Brintz C, Cheatle M, Doorenbos A, Heapy A, Keefe F, Krebs E, Kuzla N, Nigwekar S, Schmidt R, Steel J, Wetmore J, White D, Kimmel P, Cukor D, Adams M, Almonte-Then S, Amonu C, Anderson L, Argega Leon A, Argyropoulos C, Ashley E, Bajana Meza M, Bansal N, Barbosa M, Barrell T, Bart G, Barton A, Beach S, Beeks L, Belcher J, Berman N, Berry D, Bhatraju E, Bishop N, Blazes C, Busch A, Cameron S, Cardona M, Casilli V, Cazes M, Chacon Palma G, Chalamidas K, Chaudry S, Chen N, Chicos I, Clark C, Collins D, Connelly L, Contreras B, Cosmin A, Crowley S, Dalton C, Dirks J, Donahue S, Dutka P, Dyer V, Edeh O, Edwards D, Edwards D, Ekor K, Esserman D, Falker C, Farkas L, Farrar J, Felson S, Flores Y, Fraticelli Ortiz D, Garcia G, Gear L, Geibel A, Gilmartin C, Goldfarb D, Goldfeld K, Goldstein A, Gong A, Grant C, Grindstaff R, Guajardo E, Guy C, Hamm M, Hammond J, Harris K, Hoffman S, Holden C, Howell H, Ikizler T, Joffe S, Joffe J, Johnson S, Kalam E, Kampman K, Keane C, Kimura G, Kirsch O, Kourany W, Krishnamurthy P, Kubrick P, Lacey P, Landis J, Lash J, Lazlo K, Lee J, Lefler J, Leon Cupe A, Lerner S, Liebschutz J, Lietz P, Linke L, Lockwood M, Luo H, Macina A, McCarthy A, McDaniels K, McLaren S, McNeil D, Meinel M, Mejia V, Mengesha B, Merriman D, Michael W, Mims R, Mishra P, Modersitzki F, Moss A, Mullins C, Munet U, O'Connell K, Okereke U, Olejniczak D, Opeke S, Pacheco-Hernandez M, Pankratz S, Park D, Payne K, Pegues H, Percy S, Pleasant S, Purdy T, Quinn D, Quintana N, Rice K, Robinson G, Roche C, Rodriguez Sosa G, Rudow G, Rudy Q, Rutledge J, Sanchez S, Sands B, Scherer J, Schopp M, Self B, Shallcross A, Silva K, Stallings T, Stauffer C, Steffen A, Stewart T, Stringfellow S, Sullivan L, Torres R, Torres J, Trejo G, Varela D, Vassilieva S, Vilchis H, Villareal D, Walsh J, Ways J, Weidner T, Weimer M, Weiner D, Weisbord S, Wilkie C, Wilkinson M, Williams S, Williams J, Wilson O, Wood V, Yabes J, Zamora G, Zaniga S. Pain Coping Skills Training for Patients Receiving Hemodialysis. JAMA Internal Medicine 2025, 185: 197-207. PMID: 39786400, PMCID: PMC11791705, DOI: 10.1001/jamainternmed.2024.7140.Peer-Reviewed Original ResearchConceptsPain coping skills trainingPain coping skills training groupUsual care groupBrief Pain InventoryUsual carePain interferenceCoping skills trainingCare groupQuality of lifePain catastrophizingPain intensityBPI interferenceOutcomes of pain intensityRandomized clinical trialsSecondary outcomesChronic painSecondary outcomes of pain intensitySkills trainingBPI interference scoreCognitive behavioral interventionProportion of participantsOutpatient dialysis facilitiesClinically meaningful improvementsPain interventionsRandomized clinical trial of patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply